Ambee Pharmaceuticals Statistics

Total Valuation

Ambee Pharmaceuticals has a market cap or net worth of BDT 1.70 billion. The enterprise value is 2.16 billion.

Market Cap	1.70B
Enterprise Value	2.16B

Important Dates

The last earnings date was Thursday, December 12, 2024.

Earnings Date	Dec 12, 2024
Ex-Dividend Date	Dec 3, 2024

Share Statistics

Ambee Pharmaceuticals has 2.40 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	2.40M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	77.25%
Owned by Institutions (%)	n/a
Float	545,941

Valuation Ratios

The trailing PE ratio is 171.17.

PE Ratio	171.17
Forward PE	n/a
PS Ratio	7.31
PB Ratio	54.58
P/TBV Ratio	54.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 118.48, with an EV/FCF ratio of -26.20.

EV / Earnings	217.54
EV / Sales	9.30
EV / EBITDA	118.48
EV / EBIT	174.56
EV / FCF	-26.20

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 15.86.

Current Ratio	0.92
Quick Ratio	0.39
Debt / Equity	15.86
Debt / EBITDA	27.08
Debt / FCF	-5.99
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 35.49% and return on invested capital (ROIC) is 1.64%.

Return on Equity (ROE)	35.49%
Return on Assets (ROA)	1.37%
Return on Capital (ROIC)	1.64%
Revenue Per Employee	438,937
Profits Per Employee	18,755
Employee Count	477
Asset Turnover	0.41
Inventory Turnover	0.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.61% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-20.61%
50-Day Moving Average	772.11
200-Day Moving Average	786.39
Relative Strength Index (RSI)	38.79
Average Volume (20 Days)	1,504

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ambee Pharmaceuticals had revenue of BDT 232.20 million and earned 9.92 million in profits. Earnings per share was 4.13.

Revenue	232.20M
Gross Profit	123.13M
Operating Income	12.36M
Pretax Income	12.37M
Net Income	9.92M
EBITDA	18.01M
EBIT	12.36M
Earnings Per Share (EPS)	4.13

Full Income Statement

Balance Sheet

The company has 33.30 million in cash and 493.39 million in debt, giving a net cash position of -460.10 million or -191.71 per share.

Cash & Cash Equivalents	33.30M
Total Debt	493.39M
Net Cash	-460.10M
Net Cash Per Share	-191.71
Equity (Book Value)	31.11M
Book Value Per Share	12.96
Working Capital	-48.23M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -80.18 million and capital expenditures -2.20 million, giving a free cash flow of -82.38 million.

Operating Cash Flow	-80.18M
Capital Expenditures	-2.20M
Free Cash Flow	-82.38M
FCF Per Share	-34.33

Full Cash Flow Statement

Margins

Gross margin is 53.03%, with operating and profit margins of 5.32% and 4.27%.

Gross Margin	53.03%
Operating Margin	5.32%
Pretax Margin	5.33%
Profit Margin	4.27%
EBITDA Margin	7.76%
EBIT Margin	5.32%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.14%.

Dividend Per Share	1.00
Dividend Yield	0.14%
Dividend Growth (YoY)	-33.33%
Years of Dividend Growth	1
Payout Ratio	34.08%
Buyback Yield	n/a
Shareholder Yield	0.14%
Earnings Yield	0.58%
FCF Yield	-4.85%

Dividend Details

Stock Splits

The last stock split was on May 29, 2014. It was a forward split with a ratio of 1.2.

Last Split Date	May 29, 2014
Split Type	Forward
Split Ratio	1.2

Scores

Ambee Pharmaceuticals has an Altman Z-Score of 2.41. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.41
Piotroski F-Score	n/a